Literature DB >> 22853794

Molecular subgroups of medulloblastoma.

Paul A Northcott1, Adrian M Dubuc, Stefan Pfister, Michael D Taylor.   

Abstract

Recent efforts at stratifying medulloblastomas based on their molecular features have revolutionized our understanding of this morbidity. Collective efforts by multiple independent groups have subdivided medulloblastoma from a single disease into four distinct molecular subgroups characterized by disparate transcriptional signatures, mutational spectra, copy number profiles and, most importantly, clinical features. We present a summary of recent studies that have contributed to our understanding of the core medulloblastoma subgroups, focusing largely on clinically relevant discoveries that have already, and will continue to, shape research.

Entities:  

Mesh:

Year:  2012        PMID: 22853794      PMCID: PMC4334443          DOI: 10.1586/ern.12.66

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  95 in total

1.  Adult medulloblastoma comprises three major molecular variants.

Authors:  Marc Remke; Thomas Hielscher; Paul A Northcott; Hendrik Witt; Marina Ryzhova; Andrea Wittmann; Axel Benner; Andreas von Deimling; Wolfram Scheurlen; Arie Perry; Sidney Croul; Andreas E Kulozik; Peter Lichter; Michael D Taylor; Stefan M Pfister; Andrey Korshunov
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

2.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

Authors:  Yoon-Jae Cho; Aviad Tsherniak; Pablo Tamayo; Sandro Santagata; Azra Ligon; Heidi Greulich; Rameen Berhoukim; Vladimir Amani; Liliana Goumnerova; Charles G Eberhart; Ching C Lau; James M Olson; Richard J Gilbertson; Amar Gajjar; Olivier Delattre; Marcel Kool; Keith Ligon; Matthew Meyerson; Jill P Mesirov; Scott L Pomeroy
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

3.  Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.

Authors:  Andrey Korshunov; Marc Remke; Wiebke Werft; Axel Benner; Marina Ryzhova; Hendrik Witt; Dominik Sturm; Andrea Wittmann; Anna Schöttler; Jörg Felsberg; Guido Reifenberger; Stefan Rutkowski; Wolfram Scheurlen; Andreas E Kulozik; Andreas von Deimling; Peter Lichter; Stefan M Pfister
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

4.  Three down and one to go: modeling medulloblastoma subgroups.

Authors:  Charles G Eberhart
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

5.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.

Authors:  David W Ellison; James Dalton; Mehmet Kocak; Sarah Leigh Nicholson; Charles Fraga; Geoff Neale; Anna M Kenney; Dan J Brat; Arie Perry; William H Yong; Roger E Taylor; Simon Bailey; Steven C Clifford; Richard J Gilbertson
Journal:  Acta Neuropathol       Date:  2011-01-26       Impact factor: 17.088

6.  Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Authors:  Silvia Buonamici; Juliet Williams; Michael Morrissey; Anlai Wang; Ribo Guo; Anthony Vattay; Kathy Hsiao; Jing Yuan; John Green; Beatriz Ospina; Qunyan Yu; Lance Ostrom; Paul Fordjour; Dustin L Anderson; John E Monahan; Joseph F Kelleher; Stefan Peukert; Shifeng Pan; Xu Wu; Sauveur-Michel Maira; Carlos García-Echeverría; Kimberly J Briggs; D Neil Watkins; Yung-mae Yao; Christoph Lengauer; Markus Warmuth; William R Sellers; Marion Dorsch
Journal:  Sci Transl Med       Date:  2010-09-29       Impact factor: 17.956

7.  Altered neural cell fates and medulloblastoma in mouse patched mutants.

Authors:  L V Goodrich; L Milenković; K M Higgins; M P Scott
Journal:  Science       Date:  1997-08-22       Impact factor: 47.728

8.  Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.

Authors:  Katja von Hoff; Wolfgang Hartmann; André Oscar von Bueren; Nicolas Ulrich Gerber; Michael Andreas Grotzer; Torsten Pietsch; Stefan Rutkowski
Journal:  Pediatr Blood Cancer       Date:  2010-03       Impact factor: 3.167

9.  Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization.

Authors:  Bobby Bhatia; Paul A Northcott; Dolores Hambardzumyan; Baskaran Govindarajan; Daniel J Brat; Jack L Arbiser; Eric C Holland; Michael D Taylor; Anna Marie Kenney
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

10.  An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET).

Authors:  H A Rogers; S Miller; J Lowe; M-A Brundler; B Coyle; R G Grundy
Journal:  Br J Cancer       Date:  2009-03-17       Impact factor: 7.640

View more
  70 in total

1.  CNS Anticancer Drug Discovery and Development Conference White Paper.

Authors:  Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

2.  MR Imaging Characteristics of Wingless-Type-Subgroup Pediatric Medulloblastoma.

Authors:  Z Patay; L A DeSain; S N Hwang; A Coan; Y Li; D W Ellison
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-03       Impact factor: 3.825

3.  Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.

Authors:  J Rodriguez-Blanco; L Pednekar; C Penas; B Li; V Martin; J Long; E Lee; W A Weiss; C Rodriguez; N Mehrdad; D M Nguyen; N G Ayad; P Rai; A J Capobianco; D J Robbins
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

4.  Post-operative diffusion weighted imaging as a predictor of posterior fossa syndrome permanence in paediatric medulloblastoma.

Authors:  Felicia H Z Chua; Ady Thien; Lee Ping Ng; Wan Tew Seow; David C Y Low; Kenneth T E Chang; Derrick W Q Lian; Eva Loh; Sharon Y Y Low
Journal:  Childs Nerv Syst       Date:  2017-02-11       Impact factor: 1.475

Review 5.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 6.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.

Authors:  Quinn T Ostrom; Haley Gittleman; Gabrielle Truitt; Alexander Boscia; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-10-01       Impact factor: 12.300

7.  Nestin Mediates Hedgehog Pathway Tumorigenesis.

Authors:  Peng Li; Eric H Lee; Fang Du; Renata E Gordon; Larra W Yuelling; Yongqiang Liu; Jessica M Y Ng; Hao Zhang; Jinhua Wu; Andrey Korshunov; Stefan M Pfister; Tom Curran; Zeng-Jie Yang
Journal:  Cancer Res       Date:  2016-08-05       Impact factor: 12.701

8.  Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors.

Authors:  Jacquelyn J Roth; Mariarita Santi; Lucy B Rorke-Adams; Brian N Harding; Tracy M Busse; Laura S Tooke; Jaclyn A Biegel
Journal:  Cancer Genet       Date:  2014-03-15

9.  Beta-hairpin hydrogels as scaffolds for high-throughput drug discovery in three-dimensional cell culture.

Authors:  Peter Worthington; Katherine M Drake; Zhiqin Li; Andrew D Napper; Darrin J Pochan; Sigrid A Langhans
Journal:  Anal Biochem       Date:  2017-07-27       Impact factor: 3.365

10.  Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma.

Authors:  Waleed Kian; Laila C Roisman; Iris M Goldstein; Abed Abo-Quider; Benzion Samueli; Nadav Wallach; Farouq Alguayn; Walid Shalata; Dina Levitas; Olga Belochitski; Daniel Levin; Eyal Fenig; Konstantin Lavrenkov; Margarita Tokar; Nir Peled; Alexander Yakobson
Journal:  JCO Precis Oncol       Date:  2020-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.